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The biogenesis of lipid droplets (LD) induced 
by serum depends on Group IVA 
phospholipase A2 (cPLA2α). This work dissects 
the pathway leading to cPLA2α  activation and 
LD biogenesis. Both processes were Ca2+-
independent, as they took place after 
pharmacological blockade of Ca2+ transients 
elicited by serum or chelation with BAPTA-
AM. The single mutation D43N in cPLA2α , 
which abrogates its Ca2+-binding capacity and 
translocation to membranes, did not affect 
enzyme activation and formation of LD. In 
contrast, the mutation S505A did not affect 
membrane relocation of the enzyme in response 
to Ca2+, but prevented its phosphorylation, 
activation, and the appearance of LD. 
Expression of specific activators of different 
mitogen-activated protein kinases showed that 
phosphorylation of cPLA2α  at Ser505 is due to 
JNK. This was confirmed by pharmacological 
inhibition and expression of a dominant-
negative form of the upstream activator 
MEKK1. LD biogenesis was accompanied by 
increased synthesis of ceramide-1-phosphate 
(C1P). Overexpression of its synthesizing 
enzyme CERK increased phosphorylation of 
cPLA2α  at Ser505 and formation of LD, while 
its downregulation blocked the phosphorylation 
of cPLA2α  and LD biogenesis. These results 
demonstrate that LD biogenesis induced by 
serum is regulated by JNK and CERK. 
 
Intracellular lipid droplets (LD) are cytosolic 
inclusions present in most eukaryotic cells, 
containing a core of triacylglycerols (TAG) and 
cholesteryl esters, surrounded by a phospholipid 
monolayer and by specific proteins, among which 
the best characterized belong to the perilipin 
family (1-3). In the last few years, the biology of 
LD has received increasing interest, due to the 
close relationship between excess of lipid storage 
in certain tissues and pathologies such as obesity, 
diabetes, or atherosclerosis (3-5). Cellular stress 
has been related with the generation of LD, which 
might play a cytoprotective role (6, 7). Therefore, 
dissecting the signaling pathways leading to LD 
formation may have important clinical 
applications in metabolic and also in 
neurodegenerative diseases like Parkinson’s and 
Alzheimer’s (8, 9). 
 
Cells generate LD from exogenous sources -free 
fatty acids or lipoproteins- but LD also appear in 
the absence of external lipids when cells are under 
stress, apparently after the recycling of membrane 
phospholipids into TAG (7). We have shown 
recently that Group IVA PLA2 (also termed 
cPLA2α) is required for LD biogenesis either after 
exogenous lipid loading (10) or during stress (7). 
Regardless of the LD-inducing situation, the 
enzyme is not involved in the synthesis of neutral 
lipids; rather, it allows the formation of LD from 
TAG-containing membranes. cPLA2α can be 
activated by several mechanisms (reviewed in 11 
and 12). It contains a Ca2+ binding domain (C2) 
that allows interaction with membrane 
phospholipids in response to increased 
intracellular Ca2+ concentrations, and the single 
substitution D43N in this domain abrogates the 
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Ca2+-dependent translocation of cPLA2α to 
membranes  (13-15). However, the increase of 
intracellular Ca2+ is not universally required, as 
several reports have shown cPLA2α activation in 
vivo under resting Ca2+ conditions (13, 16-19). In 
this regard, anionic phospholipids like 
phosphatidylinositol (4,5)-bisphosphate (PtdIns 
4,5P2) (20, 21) and ceramide-1-phosphate (C1P) 
(22-25) bind specific regions of the enzyme and 
decrease its Ca2+ requirement to interact with 
membranes. Also, phosphorylation of cPLA2α at 
Ser residues 505, 515, and 727 appears to play a 
role in enzyme activation (11, 12). Among these 
sites, it is generally accepted that Ser505 is the one 
that leads to increased catalytic activity (26), and 
phosphorylation of Ser505 depends on mitogen-
activated protein kinases (MAPK), among which 
most reports implicate ERK and p38 (11, 12).  
 
Recently, we have shown that phosphorylation of 
cPLA2α at Ser505 is key for LD biogenesis, as 
evidenced by the inability of the S505A mutant to 
recapitulate the effect of the endogenous enzyme 
(10). The present work was undertaken to 
delineate the mechanism of cPLA2α activation that 
generates LD in the cell after serum addition. In 
essence, we show that the activation of cPLA2α is 
independent of increases of intracellular Ca2+; 
further, we identify c-Jun N-terminal kinase (JNK) 
as the MAPK implicated in cPLA2α activation. 
Finally, we show that ceramide kinase (CERK), 
the enzyme responsible for the synthesis of C1P, 
mediates LD biogenesis by inducing the 
phosphorylation of cPLA2α by JNK. 
 
Experimental procedures 
 
Materials—Nile red, primuline, trypsin, U73122 
and C1P were from Sigma-Aldrich. SP600125, 
SB20358, PD98059 and N-acetyl-D-sphingosine 
(C2-ceramide) were from Calbiochem, and 
methylarachidonyl fluorophosphonate (MAFP) 
from Cayman Chemical Co. [5,6,8,9,11,12,14,15 -
3H]Arachidonic acid ([3H]AA) (200 Ci/mmol) was 
purchased from American Radiolabeled 
Chemicals, and [9,10(n)-3H]palmitic acid (49 
Ci/mmol) from Amersham Pharmacia Biotech. 
OPTIMEM was from Gibco. Rabbit anti-cPLA2α, 
anti-phospho-Ser505-cPLA2α, anti-JNK, anti-
phospho-Thr183/Tyr185-JNK, anti-p38, anti-
phospho-Thr180/ Tyr182-p38, anti-p44/42 and 
anti-phospho-Thr202/Tyr204-p44/p42 antibodies 
were from Cell Signaling, chicken anti-ADRP 
from GenWay Biotech, rabbit anti-GAPDH from 
Ambion, and rabbit anti-CERK from Abcam.  
 
Cells— CHO-K1 cells were cultured in Ham’s F-
12 medium (Sigma-Aldrich), containing 7.5% 
fetal bovine serum (FBS, from Sigma-Aldrich), 
100 units/ml penicillin, and 100 µg/ml 
streptomycin (both from Invitrogen). Cell passages 
were made once a week by trypsinization. For the 
experiments, cells were seeded at a density of 
30,000 cells/ml in 24- (0.5 ml) or 6-well (2 ml) 
plates and maintained in FBS-containing medium 
during 48 hours. Before LD induction, cells were 
switched to serum-free culture medium for 24 
hours to set control conditions with minimal 
occurrence of LD (7). When indicated, cells (40–
70% confluence) were transfected with 1 µg 
plasmid/ml using Lipofectamine PlusTM, following 
the manufacturer's instructions. 
Nile red staining and fluorescence microscopy— 
Cells cultured on glass bottom culture dishes were 
washed with phosphate-buffered saline (PBS), 
fixed with 3% paraformaldehyde for 10 minutes, 
and washed twice with PBS. Cells were overlaid 
with 0.5 ml PBS, to which 2.5 µl of a stock 
solution of Nile red in acetone (0.2 mg/ml) were 
added, so that the final concentrations of Nile red 
and acetone were 1 µg/ml and 0.5%, respectively. 
Samples were kept in the dark until photographed 
in a Leica Qwin 500 microscope with a Leica 
DC200 camera, using the Leica DCviewer 3.2.0.0 
software. 
Flow cytometry— Indirect quantification of LD by 
flow cytometry in Nile red-stained cells was 
performed as described previously (7, 10). Briefly, 
paraformaldehyde-fixed cells were stained with 
1 µg/ml Nile red during 45 min, and analyzed with 
a Cytomics FC 500 (Beckman Coulter) equipped 
with an argon laser (488 nm), in the FL1 channel 
(505-545 nm). After gating out cellular debris, 
30,000 events were acquired in all the assays, in 
linear scale. Fluorescence intensities were 
quantified as the median value of each distribution 
of events. 
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[3H]Arachidonic release—Stimulated [3H]AA 
release from cells, which is an estimate of cPLA2α 
activity, was measured as described (7, 10, 27). 
Ca2+ imaging— Cells grown onto poly-lysine 
coated coverslips were incubated with the Ca2+ 
indicator Fura-2/AM at 4 µM in Krebs buffer of 
the following composition (in mM): (119 NaCl, 
4.75 KCl, 5 NaHCO3, 1.2 MgSO4, 1.18 KH2PO4, 
1.3 CaCl2, 20 Hepes, and 5 glucose, pH 7.4). After 
1 hour, cells were washed and coverslips mounted 
in a static chamber on an inverted Nikon TE2000U 
microscope with a conventional epifluorescence 
system. Cells were excited alternatively at 340 and 
380 nm, and emission light collected at 510 nm 
every 4-10s using a 12 bit-CCD ERG ORCA 
Hamamatsu camera. Ratio image of cells was 
analyzed using the Metafluor software (Universal 
Imaging). 14-20 cells were analyzed in each 
experiment. 
Western blots— Cells were lysed with 62.5 mM 
Tris-HCl buffer, pH 6.8, containing 2% SDS, 10% 
glycerol, 50 mM dithiotreitol, and 0.01% 
bromophenol blue, and around 20 µg of protein 
were separated by standard 10% SDS-PAGE and 
transferred to nitrocellulose membranes. Primary 
(1:1,000) and secondary antibodies (1:5,000) were 
diluted in 25 mM Tris-HCl buffer, pH 7.4, 
containing 140 mM NaCl, 10% defatted dry milk, 
0.1% bovine serum albummin and 0.1% Tween 
20. Antibody binding was detected using the 
enhanced chemiluminescence (ECL) detection kit 
(Amersham Biosciences) and visualized using a 
GeneGenome HR chemiluminiscence detection 
system coupled to a CCD camera or with High 
Performance Chemiluminiscence Films 
(Amersham Biosciences). 
siRNA transfection— We used three short 
interfering RNA (siRNA) duplexes from Gene 
Link, targeting accession number NM_022766 
(human CERK mRNA): CERK1-[537], CERK2-
[1377], and CERK3-[1679], with the following 
sequences: 5’-GGACAAGGCAAGCGGATA 
UTT (sense), and 5’-TTCCUGUUCCGUUCG 
CCUAUA (AS) for siRNA CERK1; 5’-
CGGAAAUGCUCCAGGUUCATT (sense), and 
5’TTGCCUUUACGAGGUCCAAGU (AS) for 
siRNA CERK2;  and 5’-ACGAGGAAU 
UGAAGAGAAUTT (sense), and 5’-TTUGCU 
CCUUAACUUCUCUUA (AS) for siRNA 
CERK3. Cells were transfected at 60% confluence 
with 30 nM siRNA, by adding to each 35 mm 
culture well 1 ml of Optimem (GIBCO) containing 
1.5 µl of the stock siRNA solution (20 µM) and 5 
µl of Lipofectamine PlusTM (1 mg/ml, from 
Invitrogen). After 5 hours, 1 ml of Ham’s F-12 
medium containing 7.5% FBS was added, and the 
cells were incubated for 72 hours, then changed to 
serum-free medium during 24 hours prior to 
treatments. When appropriate, labeling with 
[3H]palmitate to monitor the formation of C1P was 
done in the last 24 hours.  
Formation of 3H-C1P— [3H]palmitate-prelabeled 
cells were stimulated with 7.5% FBS during 15 
min, harvested on ice, washed with 1 ml PBS and 
centrifuged prior to extraction of lipids (28). To 
separate C1P, 0.2 ml aliquots of the chloroform 
phases were evaporated under vacuum, dissolved 
in 15 µl of chloroform / methanol (3:1, v/v), and 
spotted onto silica gel G thin layer 
chromatography plates (Merck), which were 
developed once in chloroform / methanol / water 
(67.5: 28.4: 4, v/v/v) and three times in hexane / 
diethyl ether / formic acid (55:45:1, v/v/v). After 
staining with primuline spray (5 mg primuline in 
100 ml of acetone/water (80/20, v/v), 
identification of ceramide and ceramide-1-
phosphate was made by co-migration with 
authentic standards. To quantify [3H]C1P, silica in 
regions of the TLC plates co-migrating with 
standard C1P were scraped into vials, which after 
addition of scintillation cocktail were counted in a 
Perkin-Elmer Tri-Carb 2810TR at a 40% 
efficiency.  
Confocal microscopy— Transiently transfected 
CHO-K1 cells were treated for 10 minutes with 5 
µM ionomycin. To monitor re-location of EGFP-
cPLA2α, EGFP-D43N-cPLA2α or EGFP-S505A-
cPLA2α, images were acquired every 60 seconds 
with a Leica TCS SP2 AOBS confocal 
microscope. 
Constructs— The construct encoding for the 
expression of a fusion protein containing N-
terminal enhanced green fluorescent protein 
(EGFP) followed by the entire sequence of the 
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human cPLA2α (EGFP-cPLA2α) was described 
elsewhere (21, 27). Those for EGFP-D43N-
cPLA2α and EGFP-S505A-cPLA2α were 
described in ref. 27 and 10, respectively. 
Transfection of pGFP-C3 (Clontech) was used as 
control. Constructs pCMV5-∆MEKK1 and pSRα-
K432M-MEKK1, encoding constitutively active 
and dominant negative forms of MEKK1, 
respectively, were kindly provided by Dr. Pura 
Muñoz-Cánoves (Centre de Regulació Genòmica, 
Barcelona). Constructs pCMV5-myc-MEKK3-EE 
and pcDNA3-MEK1-EE, encoding constitutively 
active MEKK3 and MEK1, were gifts from Dr. 
Ana Cuenda (Centro Nacional de Biotecnología, 
CSIC-Universidad Autónoma de Madrid, Madrid) 
and Dr. Piero Crespo (Instituto de 
Investigaciones Biomédicas, CSIC-Universidad 
de Cantabria, Santander), respectively. The 
construct for CERK expression (pcDNA3.1 
HisTOPO-hCERK) is described elsewhere (29).  
 
Statistical analysis— Data analysis was carried 
out with Prism software (GraphPad). Responses 
among different treatments were analyzed with 
one-way analysis of variance followed by 
Bonferroni’s multiple comparison test. All 
experiments were carried out with determinations 
in triplicate. Most results are presented as means ± 
SEM of three independent experiments, except 
those in Figure 8B, which are means ± range of 
two experiments. Results shown as fluorescence 
Ca2+ signals, western blots or microphotographs 
are representative of at least three independent 
experiments with essentially the same outcome. 
 
Results 
 
The activation of cPLA2α required for LD 
biogenesis is independent of Ca2+—Serum-starved 
cells challenged with 7.5% FBS produced 
transient Ca2+ increases (Figure 1A). As expected, 
this Ca2+ signal disappeared when cells were 
pretreated with 45 µM BAPTA-AM during 30 
minutes prior to stimulation with FBS (Figure 1A). 
The inhibitory effect of BAPTA-AM was 
confirmed after the inability of ionomycin to 
induce a Ca2+ response (not shown). cPLA2α was 
phosphorylated upon FBS stimulation when 
intracellular Ca2+ increases were abrogated by 
BAPTA-AM (Figure 1B), and in fact cPLA2α 
activity, measured as [3H]AA release to the 
medium, was unaffected by intracellular Ca2+ 
chelation (Figure 1D). This Ca2+-chelating strategy 
was toxic over 6 hours, however, and did not 
allow us to measure LD levels, which we usually 
monitor after a 6-hour treatment (7, 10).  Instead, 
we used the phosphoinositide phospholipase C 
inhibitor U73122 to block the Ca2+ signals induced 
by FBS, which are due to the generation of inositol 
1,4,5-trisphosphate (30). As shown in Figure 1A, 
pretreatment with 10 µM U73122 blocked the Ca2+ 
response but it did not affect phosphorylation of 
cPLA2α at Ser505 (Figure 1C) or [3H]AA 
releasing activity (Figure 1D). Importantly, in the 
presence of the phospholipase C inhibitor, FBS 
still promoted ADRP expression (Figure 1C) and 
LD biogenesis that was sensitive to the cPLA2α 
inhibitor MAFP (Figure 1E).  
 
Additional evidence for a Ca2+-independent 
activation of cPLA2α during LD biogenesis came 
from the transfection of a D43N-cPLA2α mutant. 
Asp43 resides in the Ca2+-binding loop 1 at the 
membrane binding face of the C2 domain of the 
enzyme, and participates in the coordination of the 
two Ca2+ ions that drive membrane binding (11). 
Substitution of this residue for Asn increases 100-
fold the Ca2+ requirement for activity in vitro (31), 
and prevents translocation of the enzyme to 
membranes in response to Ca2+ ionophores (15, 
27). In agreement with this, EGFP-D43N-cPLA2α 
did not relocate in CHO-K1 cells stimulated with 5 
µM ionomycin, unlike the wild type enzyme, 
which translocated to perinuclear membranes and 
structures resembling the Golgi apparatus (Figure 
2A-D). In contrast, EGFP-S505A-cPLA2α, which 
lacks the Ser505 phosphorylation site but retains 
its Ca2+ binding capacity, translocated to 
membranes in response to ionomycin just as the 
wild type enzyme (Figure 2E-F). Importantly, FBS 
treatment induced phosphorylation of wild type 
and D43N cPLA2α, at Ser-505 (Figure 2G). 
Further, transfection of EGFP-D43N-cPLA2α 
resulted in increased release of [3H]AA (Figure 
2H), both under basal conditions and upon FBS 
stimulation, to the same levels achieved by 
transfection of EGFP-cPLA2α. Regarding LD 
occurrence, the effect of the D43N mutant was 
identical to the wild type enzyme: there was a 2.5-
fold increase of LD upon FBS stimulation, 
monitored either by flow cytometry (Figure 2I), 
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ADRP content (not shown) or by fluorescence 
microscopy (Figure 2J, K).  Taken together, these 
results demonstrate that the activation of cPLA2α 
and biogenesis of LD induced by FBS are 
independent of Ca2+ and do not require massive 
relocation of the enzyme. Further, the results 
confirm our previous finding that phosphorylation 
of cPLA2α at Ser505 is essential for its activation 
by FBS, while there is no apparent relocation in 
response to the faint Ca2+ signal elicited by the 
stimulus (10). 
 
JNK, but not ERK or p38 MAP kinases, is 
responsible for cPLA2α phosphorylation and LD 
biogenesis—cPLA2α is phosphorylated at Ser505 
by MAPKs (11, 12), and to dissect the pathway 
during LD biogenesis, we monitored JNK, p38 
and ERK MAPKs at different times after FBS 
replacement. As shown in Figure 3, all three 
MAPKs became activated after stimulation with 
7.5% FBS. We therefore activated each MAPK 
individually by transfecting constitutively active 
upstream activators of each pathway. As shown in 
Figure 4A, transfection of the catalytic domain of 
MEKK1, which encodes a constitutively active 
kinase (∆MEKK1) induced phosphorylation of 
JNK in the absence of FBS stimulus, but not of 
ERK and only a slight increase of p38. Likewise, 
transfection of MKK3EE and MEK1EE resulted in 
the specific phosphorylation of p38 and ERK, 
respectively, in the absence of FBS. Importantly, 
only the activation of JNK increased 
phosphorylation of cPLA2α at Ser505 (Figure 4A), 
and this was inhibited in the presence of the JNK 
inhibitor SP600125 at 10 µM (not shown). 
∆MEKK1-JNK-mediated phosphorylation of 
cPLA2α was mirrored by an increased [3H]AA-
releasing activity in the absence of FBS stimulus, 
which again was inhibited by SP600125 and also 
by MAFP (Figure 4B). In contrast, [3H]AA 
released from cells transfected either with 
MKK3EE or MEK1EE was not different from that 
in control cells (Figure 4B). In close agreement 
with data on cPLA2α phosphorylation and activity, 
Figure 4C shows that cells transfected with 
∆MEKK1 had increased LD content as monitored 
by flow cytometry. In contrast, stimulation of p38 
or ERK did not induce the formation of LD. 
Again, LD biogenesis induced by expression of 
∆MEKK1 in the absence of FBS stimulus was 
sensitive to inhibition by SP600125 and MAFP. 
 
The preceding results show that the JNK inhibitor 
SP600126 antagonizes the activation of cPLA2α 
and the biogenesis of LD in the absence of a FBS 
stimulus. In order to validate this pharmacological 
evidence in a more physiological setting, we 
compared the ability of MAPK inhibitors to block 
cPLA2α activation and LD biogenesis induced by 
FBS. As shown in Figure 5A, phosphorylation of 
cPLA2α induced by 7.5% FBS was inhibited in the 
presence of 10 µM SP600125, but was not 
affected by the same concentration of the p38 
inhibitor SB20358 or the MEK inhibitor PD98059. 
In close agreement with these results, [3H]AA 
release stimulated by FBS was only decreased in 
the presence of the JNK inhibitor but was 
unaffected by SB20358 or PD98959 (Figure 5B). 
Further, the occurrence of LD induced by FBS, 
monitored either by flow cytometry (Figure 5C) or 
after the expression of ADRP (Figure 5A) was 
sensitive only to the JNK inhibitor. 
 
We also inhibited JNK by transfecting a dominant-
negative form of MEKK1, the upstream activator 
of JNK. Figure 6A shows that phosphorylation of 
JNK in response to FBS stimulation was partially 
inhibited in cells transfected with K432M-
MEKK1, as compared to cells transfected with 
empty vector. The partial inhibition of JNK was 
enough to fully inhibit cPLA2α phosphorylation 
induced by FBS (Figure 6A). In close agreement 
with this, cPLA2α activity monitored after the 
release of [3H]AA (Figure 6B) and LD biogenesis 
measured by flow cytometry (Figure 6C) were 
clearly inhibited by transfection of K432M-
MEKK1. Results on the inhibition of LD were 
confirmed by ADRP expression levels (not shown) 
and by fluorescence microscopy. Panels D and E 
of Figure 6 show that, unlike cells transfected with 
empty vector, which generate LD after FBS 
replacement, those transfected with K432M-
MEKK1 do not contain LD. Taken together, these 
results demonstrate that the MAP kinase that 
activates cPLA2α during LD biogenesis is JNK. 
 
Ceramide-1-phosphate induces LD biogenesis in 
the absence of FBS— Next, we assessed the 
possible implication of C1P in cPLA2α activation 
in our system. C1P drives the translocation of 
cPLA2α to membranes and is absolutely required 
for its activation in response to inflammatory 
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agonists (25), but it also might contribute to the 
phosphorylation state of the enzyme (32). We 
treated serum-starved cells with 2.5 µM C1P in 
ethanol:dodecane (98:2) at a final vehicle dilution 
of 1:1000 (33). C1P induced both JNK and 
cPLA2α phosphorylation (figure 7A). Also, C1P 
stimulated the release of [3H]AA in a SP600125- 
and MAFP-sensitive fashion, to levels that were 
similar to those attained with FBS stimulation 
(Figure 7B). In contrast to C1P, C2-ceramide at the 
same concentration did not affect JNK and 
cPLA2α phosphorylation or cPLA2α activity. In 
agreement with these results, C1P induced LD 
biogenesis that was inhibited by SP600125 and 
MAFP (Figure 7C). LD quantification with flow 
cytometry agreed with ADRP expression levels 
and epifluorescence microscopy (not shown). To 
confirm results on exogenously supplied C1P, we 
overexpressed CERK, the enzyme responsible for 
C1P synthesis. Expression of CERK in CHO-K1 
cells induced the phosphorylation of JNK and 
cPLA2α (Figure 7D). Further, the synthesis of C1P 
was enhanced, and this was accompanied by the 
stimulation of cPLA2α activity and the biogenesis 
of LD (Figure 7E-G). These results indicate that 
an increase of C1P can induce LD formation 
through JNK activation and subsequent cPLA2α 
phosphorylation at Ser505. 
 
FBS increases C1P, and silenced expression of 
CERK inhibits the formation of LD induced by 
FBS— To tackle the relevance of the latter set of 
results, we knocked down the expression of CERK 
with a siRNA approach. Among the three different 
siRNA sequences used, two of them (siRNA 
CERK1 and siRNA CERK3) effectively 
downregulated the enzyme, whereas siRNA 
CERK2 had no effect (figure 8A). Figure 8B 
shows that FBS stimulation increased the synthesis 
of [3H]C1P in [3H]palmitate-prelabeled cells, and 
this was blocked by siRNA CERK1 and siRNA 
CERK3 but not by siRNA CERK2. We did not 
observe changes in [3H]ceramide content under 
any condition (not shown). CERK downregulation 
also inhibited the phosphorylation of JNK and 
cPLA2α induced by FBS (Figure 8A). Further, 
knocked-down expression of CERK inhibited 
[3H]AA release (Figure 8C) and LD biogenesis 
monitored by flow cytometry (Figure 8D), ADRP 
expression (Figure 8A), or by fluorescence 
microscopy (not shown). In conclusion, the above 
results show that serum-induced LD biogenesis is 
mediated by CERK and formation of C1P. 
 
Discussion 
 
The present work addresses the mechanism of 
cPLA2α activation needed for the biogenesis of 
LD induced by FBS. Our findings can be 
summarized in three major points: First, cPLA2α 
activation and LD biogenesis are independent of 
intracellular Ca2+ rises, with no apparent relocation 
of the enzyme. Second, JNK is the MAPK that 
activates cPLA2α in our experimental model. And 
third, the C1P-generating enzyme CERK is 
required for the activation of JNK, and hence of 
cPLA2α. 
 
This study shows that the pathway leading to 
cPLA2α activation and LD biogenesis is Ca2+ 
independent. Intracellular chelation with BAPTA-
AM or blocking of the Ins1,4,5P3-induced Ca2+ 
transient elicited by FBS does not alter cPLA2α 
activation and LD biogenesis. Moreover, the 
single mutation D43N in the C2 domain of the 
enzyme, which abrogates its Ca2+-binding 
capacity, does not affect activity in response to 
FBS.   Several reports have established the 
dispensability of Ca2+ rises in terms of full enzyme 
activation in vivo (13, 16-19) while putting 
forward the requirement of the signaling lipids 
PtdIns4,5P2 (17, 20, 21, 34) and C1P to allow 
interaction with membranes (22-25). The D43N 
mutation in cPLA2α renders the enzyme refractory 
to physiological Ca2+ concentrations (31) but it is 
fully active on PtdIns4,5P2-containing micelles 
(34). We have not addressed the possible role of 
PtdIns4,5P2 in LD biogenesis, but in light of the 
present results this is certainly a goal in the near 
future. It is now clear that cPLA2α activity is 
essential for the generation of LD after TAG 
present in the ER (7, 10), however we have 
consistently found no enzyme translocation to the 
nuclear envelope and nearby membranes in 
response to FBS (10). Bearing in mind that the 
D43N mutation does not suppress interfacial 
activity of the C2 domain (34), in our 
experimental model the enzyme could interact 
with the diffuse RE membrane system and/or 
nascent LD. This would probably escape detection 
in our studies, which were carried out within 
minutes following FBS stimulation (10). 
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Our results show that JNK regulates cPLA2α 
activation and LD biogenesis by inducing 
phosphorylation at Ser505. Although 
phosphorylation at this site increases activity in 
vitro only 2-fold (11), it confers increased 
membrane affinity at low micromolar Ca2+ 
concentrations (11, 12), and this tighter binding to 
the lipid surface could become critical for enzyme 
activation under our resting Ca2+ conditions. FBS 
activates ERK, p38 and JNK, and we identify the 
JNK cascade as the one governing cPLA2α 
phosphorylation in our system. This also stands 
probably for oleate-induced LD1. A literature 
survey shows that the identity of the MAPK 
cascade leading to the phosphorylation of cPLA2α 
at Ser505 is a matter of cell type and triggering 
stimulus, often involving ERK or/and p38 MAPK. 
However, to our knowledge only two recent 
reports have uncovered a key role of JNK in 
cPLA2α-activation, both related to the 
microbicidal activity of phagocytes: Lee et al. (35) 
showed that secretion of monocyte 
chemoattractant protein-1 induced by stimulation 
of macrophages with synthetic 
oligodeoxynucleotides containing CpG motifs 
depends on cPLA2α activity, which can be blocked 
by pharmacological inhibition or downregulation 
of JNK. Casas et al. (36), on the other hand, 
showed that translocation of cPLA2α to 
phagosomal membranes of macrophages, an event 
required for eicosanoid generation and killing of 
the ingested microbe, requires enzyme 
phosphorylation at Ser505 and is blocked after 
pharmacological inhibition of JNK. The present 
paper, therefore, describes for the first time the 
crucial role of the JNK cascade in the activation of 
cPLA2α for LD biogenesis. We showed previously 
that the implication of cPLA2α in LD biogenesis 
after serum lipoproteins is not unique to the CHO 
cell model (10). It remains to be established 
whether this generalization also stands for JNK, as 
it may hold promise for new pharmacological 
approaches in the treatment of metabolic diseases. 
In this regard, LDs have been shown to interfere 
with membrane translocation of the insulin-
sensitive glucose transporter, an observation that 
might account for insulin resistance in type 2 
                                                
1 Gubern, A. and Claro, E., unpublished results 
diabetes (5). It is tempting to speculate, therefore, 
that the observation that animal models of obesity 
have abnormally elevated JNK activity, and that 
JNK1 knock-out mice on obesity-inducing diets 
are protected against adiposity and insulin 
resistance (37) are related to cPLA2α-mediated 
formation of LD.  
 
This report also presents CERK and its product 
C1P as new key players in the biogenesis of LD. 
This is somehow not surprising, as C1P is a firmly 
established activator of cPLA2α (32, 38). C1P also 
has pro-survival effects (39), in line with the 
protective role that LD play during nutrient 
starvation and other stress conditions (6, 7). C1P 
interacts with the cationic β-groove (Arg57, 
Lys58, Arg59) of the C2 domain of cPLA2α. This 
enhances interaction with membranes and lowers 
the EC50 for Ca2+ down to 31 nM, resulting in 
increased and catalytic activity in vitro (22, 24). 
Recently, it has been described that CERK is 
required for cPLA2α activation and translocation 
to the Golgi in response to Ca2+ increases in the 
cell (25). Our results clearly show the requirement 
of CERK for cPLA2α activation and LD 
biogenesis. However, they do not quite fit with a 
direct interaction of C1P and cPLA2α: first, 
cPLA2α activation for LD biogenesis is 
independent of Ca2+, and it does not require 
enzyme translocation to the nuclear envelope and 
the Golgi; second, our data show that CERK 
activates JNK and downstream phosphorylation of 
cPLA2α at Ser505. This suggests that C1P does 
not solely promote association of the enzyme with 
membranes. Our data fully support a formerly 
proposed mechanism (32, 40) whereby C1P 
activates the JNK cascade, either directly or after 
the inhibition of protein phosphatases 1 and 2A. 
This mechanism is in keeping with our 
observation that okadaic acid induces LD 
biogenesis in a JNK- and cPLA2α-dependent 
fashion1. Regardless of the mechanism, our results 
clearly point CERK as a potential target for the 
treatment of metabolic diseases. 
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Footnotes 
1- Gubern, A., and Claro E., unpublished results. 
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Figure legends 
 
Figure 1: FBS activates cPLA2α and induces LD biogenesis in the presence of BAPTA-AM or 
U73122 
A: Ca2+ responses of serum-starved, fura-2/AM-loaded CHO-K1 cells under control conditions 
(continuous line) or after pre-treatment with 45 µM BAPTA-AM (circles) or 10 µM U73122 (triangles) 
for 30 minutes before fluorescence measurements were started. At the time indicated, 7.5% FBS was 
added. B, C: Western blots of serum-starved CHO-K1 pre-treated with 45 µM BAPTA-AM or 10 µM 
U73122 during 30 minutes, then stimulated with 7.5% FBS for 6 hours. D: cPLA2 activity, measured after 
the radioactivity released to the medium of serum-starved CHO-K1 cells that had been prelabeled during 
24 hours with 0.5 µCi/ml [3H]arachidonic acid, then washed and treated with 45 µM BAPTA-AM, 10 µM 
U73122 and/or 10 µM MAFP for 30 minutes before a 15-min stimulation with 7.5% FBS. E: Indirect 
quantification of LD in serum-starved CHO-K1 cells that had been pretreated for 30 minutes with 10 µM 
U73122 and/or MAFP, then stimulated with 7.5% FBS for 6 hours. Cells were fixed and stained with Nile 
red to quantify LD by flow cytometry. Fluorescence intensities in FL1 were quantified as the median 
values of each event distribution. Results in panels C and D are means ± SEM of three independent 
experiments. *Significantly different (p < 0.01) from controls. 
 
Figure 2: EGFP-D43N-cPLA2α  is as effective as EGFP-cPLA2α  to induce LD biogenesis in 
response to FBS 
A-F: CHO-K1 cells were transiently transfected with plasmids encoding EGFP-cPLA2α (A, B), EGFP-
D43N-cPLA2α (C, D) or EGFP-S505A-cPLA2α (E, F). Confocal images were obtained before (A, C, E) 
or 10 min after addition of 5 µM ionomycin. G: Western blots of total cPLA2α and phospho-Ser505-
cPLA2α of transiently transfected cells. H: [3H]AA release from serum starved CHO-K1 cells transfected 
with EGFP-cPLA2α, EGFP-D43N-cPLA2α or EGFP-S505A-PLA2α, and kept unstimulated (open bars) 
or stimulated with 7.5% FBS for 15 minutes (filled bars). I: Indirect quantification of LD by flow 
cytometry in cells after 6 hours under control conditions (open bars) or with 7.5% FBS (filled bars). J, K: 
Serum-starved CHO-K1 cells transiently transfected with EGFP-D43N-cPLA2α (J) or with EGFP-
S505A-PLA2α (K) were stained with Nile red for epifluorescence microscopy. Results in panels H and I 
are means ± SEM of 3 independent experiments. *Significantly different (p < 0.01) from GFP-transfected 
cells. #Significantly different (p < 0.01) from FBS-stimulated, GFP-transfected cells. 
 
Figure 3: FBS induces the phosphorylation of JNK, p38 and ERK in CHO-K1 cells 
Serum-starved CHO-K1 cells were treated with 7.5% FBS for the indicated times. Total and 
phosphorylated JNK, p38, and ERK were monitored by western blot. 
 
Figure 4: The activation of JNK, but not of p38 or ERK, is sufficient to phosphorylate cPLA2α  and 
induce LD biogenesis in the absence of FBS 
CHO-K1 cells were transiently transfected with plasmids encoding ∆MEKK1, MEKK3EE or MEK1EE 
and switched to culture medium without FBS. A: Phosphorylation of JNK, p38, ERK and cPLA2α in the 
absence of FBS. B: Cells were prelabeled with 0.5 µCi/ml [3H]AA during 24 hours, then washed, and the 
release of radioactivity to the medium was quantified after 15 min. C: indirect quantification of LD by 
flow cytometry. Results in panels B and C are means ± SEM of three independent experiments. 
*Significantly different (p < 0.01) from control. 
 
Figure 5: The JNK inhibitor SP600125 prevents cPLA2α  activation and LD biogenesis induced by 
FBS. 
Serum-deprived CHO-K1 cells were pretreated for 30 minutes with 10 µM concentrations of SP600125, 
SB20358, or PD98059, and then challenged with 7.5% FBS for 15 minutes (B) or 6 hours (A, C). A: 
 JBC
 
C
 o
 n
 f 
i d
 e 
n 
t i
 a
 l
 12 
Western blots of total cPLA2α, phospho-Ser505-cPLA2α, and ADRP. B:  Radioactivity released from 
serum-deprived CHO-K1 cells that were prelabeled during 24 hours with 0.5 µCi/ml [3H]AA, washed, 
and pretreated with drugs for 30 minutes before a 15-min stimulation with 7.5% FBS. C: Serum-starved 
cells were treated for 30 min with drugs, then stimulated with FBS during 6 hours, fixed and stained with 
Nile red to quantify LD by flow cytometry. Results in panels B and C are means ± SEM of three 
independent experiments. *p < 0.01 compared to control in the absence of FBS. #p < 0.01 compared to 
FBS-treated cells. 
 
Figure 6: Transfection of a dominant negative form of MEKK1 (K432M-MEKK1) inhibits JNK 
phosphorylation, activation of cPLA2α  and LD biogenesis 
CHO-K1 cells were transfected with empty vector or vector encoding K432M-MEKK1. Cells were 
serum-starved for 24 hours and then challenged for 15 minutes (A, B) or 6 hours (C) with 7.5% FBS. A: 
Phosphorylation levels of JNK and cPLA2α. B: radioactivity released from cells that had been prelabeled 
during 24 hours with 0.5 µCi/ml [3H]AA. C: Indirect quantification of LD by flow cytometry. D, E: Cells 
were transfected with empty vector (D) or with vector encoding K432M-MEKK1 (E), stimulated for 6 
hours with 7.5% FBS, and stained with Nile red for epifluorescence microscopy. Results in panels B and 
C are means ± SEM of three independent experiments. *Significantly different (p < 0.01) from control. 
 
Figure 7: C1P and CERK stimulate cPLA2α  and induce LD biogenesis 
A: Western blots of phospho-JNK and phospho-cPLA2α from serum-starved CHO-K1 cells that were 
treated with vehicle, 2.5 µM C2-ceramide, 2.5 µM C1P or 7.5 % FBS for 15 minutes. B: Radioactivity 
released from [3H]AA prelabeled, serum-starved cells that were pretreated for 30 min with  MAFP or 
SP600125, then stimulated for 15 min with C2-Cer, C1P or FBS. C: Quantification of LD by flow 
cytometry after a 6-hour treatment with C2-Cer, C1P of FBS. D-G: Cells were transiently transfected with 
a plasmid encoding CERK, then maintained in the absence of FBS. Overexpression of CERK increased 
the phosphorylation of JNK and cPLA2α (D). CERK-transfected cells were prelabeled for 24 hours with 
[3H]palmitate or with [3H]AA to monitor synthesis of C1P (E) and cPLA2α activity (F), respectively. 
CERK also increased basal levels of LD in the absence of FBS (G). *Significantly different (p < 0.01) 
from control. 
 
Figure 8: CERK is required for the activation of JNK and cPLA2α ,  and for LD biogenesis 
CHO-K1 cells were transfected with three siRNA-CERK duplexes as described in Methods, and 
maintained in 7.5% FBS-containing medium during 72 hours, then in medium without FBS for 24 hours. 
During these last 24 hours, cells were prelabeled with [3H]palmitate or with [3H]AA to monitor synthesis 
of C1P and cPLA2α activity, respectively (B, C). A: Western blots showing that siRNA-CERK1 and 
siRNA-CERK3 knocked down the expression of CERK, precluded phosphorylation of JNK and cPLA2α 
induced by a 6-hour treatment with FBS, and decreased ADRP content. FBS treatment was B: 
[3H]palmitate-prelabeled cells were stimulated with FBS during 15 min. Lipid extracts were separated by 
TLC, and areas co-migrating with C1P standard were scraped onto vials and counted. C: [3H]AA-
prelabeled cells were stimulated with FBS during 15 min, and radioactivity in the medium was counted. 
D: Cells were stimulated with FBS during 6 hours, fixed, stained with Nile red, and LD were quantified 
by flow cytometry. Results in panels C and D are means ± SEM of three experiments. Results in B are 
means ± range of two experiments. *Significantly different (p < 0.01) from controls. 
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